Seqens Seqens

X
[{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Drug to Prevent Chest Pain in Heart Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3176

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Imdur-Generic (isosorbide mononitrate) is a soluble guanylate cyclase activator which is approved by USFDA for the treatment of chest pain (angina) in patients with a certain heart condition.

            Lead Product(s): Isosorbide Mononitrate

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Imdur-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY